IPSC Profile
Century Therapeutics, Inc. is a biotechnology company at the forefront of developing innovative allogeneic cell therapies aimed at treating solid tumors and hematological malignancies. The company specializes in creating transformative therapies using induced pluripotent stem cells (iPSCs) to generate chimeric antigen receptor (CAR) cells and innate immune cells (iNK and iT cells). These therapies are designed to target and eliminate cancer cells with high precision. Century Therapeutics' approach leverages the unique properties of iPSCs to produce off-the-shelf cell therapies that offer significant advantages in terms of scalability and accessibility.
The company's lead product candidate, CNTY-101, represents a significant advancement in the field of cell therapy. CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy specifically engineered to target CD19, a common antigen found on relapsed and refractory B-cell lymphoma cells. This therapy aims to provide a novel treatment option for patients with challenging B-cell malignancies who have exhausted other therapeutic options. In addition to CNTY-101, Century Therapeutics is advancing several other promising candidates, including CNTY-103, which targets both CD133 and EGFR for recurrent glioblastoma, a particularly aggressive form of brain cancer.
The company's pipeline also includes CNTY-102, a CAR-iT cell therapy targeting CD19 and CD79b, designed to address relapsed and refractory B-cell lymphoma and other B-cell malignancies. CNTY-104 and CNTY-106 are multi-specific candidates targeting acute myeloid leukemia (AML) and multiple myeloma, respectively. CNTY-104 combines CAR-iT or CAR-iNK technologies to target multiple antigens associated with AML, while CNTY-106 aims to tackle multiple myeloma with a similar multi-specific approach. These therapies reflect Century Therapeutics’ commitment to developing versatile and effective treatments for a range of difficult-to-treat cancers.
Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics is strategically positioned to drive forward its innovative cell therapy pipeline. The company’s use of iPSCs to create off-the-shelf therapies represents a significant leap in the field of cancer treatment, offering potential solutions for patients with severe and refractory malignancies. With its robust pipeline and cutting-edge technology, Century Therapeutics is poised to make a substantial impact on the future of oncology and cell-based therapies.
|
